Skip to main content

Table 3 Multivariate Cox proportional hazard models for the predictors of progression free-survival

From: Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study

Factors Univariate PFS   Multivariate PFS  
  HR (95% CI) P HR (95% CI) P
Age > 65, yes 0.51 (0.31–0.87) 0.013 0.52 (0.31–0.88) 0.014
Male, yes 1.10 (0.72–1.69) 0.66 1.02 (0.65–1.56) 0.95
Favorable prognosis, yes 1.43 (0.95–2.14) 0.084 1.41 (0.93–2.1) 0.099
Karnofsky performance status ≥90, n (%) 1.18 (0.79–1.76) 0.43
≥ 2 metastatic sites, n (%) 1.35 (0.90–2.01) 0.15
Hemoglobin, g/dL 0.98 (0.87–1.10) 0.69
Leucocytes, 109/L 1.03 (0.92–1.15) 0.59
Neutrophils, 109/L 1.03 (0.91–1.17) 0.65
Platelets, 109/L 1.00 (1.00–1.005) 0.044
Total calcium, mg/dL 1.074 (0.83–1.38) 0.58
LDH, mg/dL 0.99 (0.99–1.00) 0.28
  1. Abbreviations: PFS Progression free-survival, HR Hazard ratio, CI Confidence interval. Favorable group was classified according to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC model), in which favorable risk is equivalent to no factors
\